Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 45.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 171,285 shares of the specialty pharmaceutical company’s stock after selling 143,816 shares during the period. JPMorgan Chase & Co. owned about 0.30% of Supernus Pharmaceuticals worth $8,186,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SUPN. Rubric Capital Management LP acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $21,908,000. Woodline Partners LP lifted its holdings in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares during the period. UBS Group AG boosted its position in shares of Supernus Pharmaceuticals by 137.6% in the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after purchasing an additional 312,775 shares during the period. Finally, Sofinnova Investments Inc. increased its stake in Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after purchasing an additional 278,575 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on SUPN. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $62.17.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the transaction, the director directly owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jack A. Khattar sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the transaction, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This represents a 3.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 120,881 shares of company stock valued at $6,139,356 in the last 90 days. Corporate insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $49.52 on Monday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $59.68. The stock’s 50-day moving average is $50.99 and its two-hundred day moving average is $49.39. The stock has a market cap of $2.85 billion, a PE ratio of -72.82, a price-to-earnings-growth ratio of 1.54 and a beta of 0.70.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.